Skip to main content
Erschienen in: Tumor Biology 3/2013

01.06.2013 | Research Article

CXCR4-mediated Stat3 activation is essential for CXCL12-induced cell invasion in bladder cancer

verfasst von: Hai-bo Shen, Zheng-qin Gu, Kang Jian, Juan Qi

Erschienen in: Tumor Biology | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

CXCL12/CXCR4 signaling plays important roles in tumor cell metastasis in many types of cancers, and CXCR4 is the key regulator of cell motility in bladder cancer. Emerging evidence suggests that transcription-3 (Stat3) activation is associated with bladder cancer cell growth and survival, while the relationship between CXCL12/CXCR4 signal and Stat3 activation remains unclear. In this study, expression analysis of bladder cancer and adjacent normal tissues showed that higher CXCR4 expression was associated with Stat3 phosphorylation. CXCR4 knockdown in bladder cancer T24 cells impaired CXCL12-induced cell invasion and Stat3 activation. Furthermore, blocking Stat3 activity with the chemical inhibitor Stattic inhibited CXCL12-triggered Stat3 phosphorylation and cell invasion in T24 cells, suggesting that Stat3 activation is required for CXCL12 function in the mobility of bladder cancer. Taken together, CXCR4 is necessary for CXCL12 signal transduction in bladder cancer, and CXCL12/CXCR4 promotes invasion of bladder cancer cells through activation of Stat3 transcriptional activity.
Literatur
1.
Zurück zum Zitat Kirkali Z, Chan T, Manoharan M, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology. 2005;66:4–34.PubMedCrossRef Kirkali Z, Chan T, Manoharan M, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology. 2005;66:4–34.PubMedCrossRef
2.
Zurück zum Zitat Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRef Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRef
4.
Zurück zum Zitat Lehmann J, Retz M, Stockle M. Is there standard chemotherapy for metastatic bladder cancer? Quality of life and medical resources utilization based on largest to date randomized trial. Crit Rev Oncol Hematol. 2003;47:171–9.PubMedCrossRef Lehmann J, Retz M, Stockle M. Is there standard chemotherapy for metastatic bladder cancer? Quality of life and medical resources utilization based on largest to date randomized trial. Crit Rev Oncol Hematol. 2003;47:171–9.PubMedCrossRef
5.
Zurück zum Zitat Zlotnik A, Burkhardt AM, Homey B. Homeostatic chemokine receptors and organ-specific metastasis. Nat Rev Immunol. 2011;11:597–606.PubMedCrossRef Zlotnik A, Burkhardt AM, Homey B. Homeostatic chemokine receptors and organ-specific metastasis. Nat Rev Immunol. 2011;11:597–606.PubMedCrossRef
6.
Zurück zum Zitat Keeley EC, Mehrad B, Strieter RM. CXC chemokines in cancer angiogenesis and metastases. Adv Cancer Res. 2010;106:91–111.PubMedCrossRef Keeley EC, Mehrad B, Strieter RM. CXC chemokines in cancer angiogenesis and metastases. Adv Cancer Res. 2010;106:91–111.PubMedCrossRef
7.
Zurück zum Zitat Strieter RM, Belperio JA, Burdick MD, et al. CXC chemokines: angiogenesis, immunoangiostasis, and metastases in lung cancer. Ann N Y Acad Sci. 2004;1028:351–60.PubMedCrossRef Strieter RM, Belperio JA, Burdick MD, et al. CXC chemokines: angiogenesis, immunoangiostasis, and metastases in lung cancer. Ann N Y Acad Sci. 2004;1028:351–60.PubMedCrossRef
8.
Zurück zum Zitat Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity. 2000;12:121–7.PubMedCrossRef Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity. 2000;12:121–7.PubMedCrossRef
9.
Zurück zum Zitat Chiu HY, Sun KH, Chen SY, et al. Autocrine CCL2 promotes cell migration and invasion via PKC activation and tyrosine phosphorylation of paxillin in bladder cancer cells. Cytokine. 2012;59:423–32.PubMedCrossRef Chiu HY, Sun KH, Chen SY, et al. Autocrine CCL2 promotes cell migration and invasion via PKC activation and tyrosine phosphorylation of paxillin in bladder cancer cells. Cytokine. 2012;59:423–32.PubMedCrossRef
10.
Zurück zum Zitat Singh S, Singh UP, Grizzle WE, et al. CXCL12-CXCR4 interactions modulate prostate cancer cell migration, metalloproteinase expression and invasion. Lab Invest. 2004;84:1666–76.PubMedCrossRef Singh S, Singh UP, Grizzle WE, et al. CXCL12-CXCR4 interactions modulate prostate cancer cell migration, metalloproteinase expression and invasion. Lab Invest. 2004;84:1666–76.PubMedCrossRef
11.
Zurück zum Zitat Dewan MZ, Ahmed S, Iwasaki Y, et al. Stromal cell-derived factor-1 and CXCR4 receptor interaction in tumor growth and metastasis of breast cancer. Biomed Pharmacother. 2006;60:273–6.PubMedCrossRef Dewan MZ, Ahmed S, Iwasaki Y, et al. Stromal cell-derived factor-1 and CXCR4 receptor interaction in tumor growth and metastasis of breast cancer. Biomed Pharmacother. 2006;60:273–6.PubMedCrossRef
12.
Zurück zum Zitat Teicher BA, Fricker SP. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res. 2010;16:2927–31.PubMedCrossRef Teicher BA, Fricker SP. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res. 2010;16:2927–31.PubMedCrossRef
13.
Zurück zum Zitat Eisenhardt A, Frey U, Tack M, et al. Expression analysis and potential functional role of the CXCR4 chemokine receptor in bladder cancer. Eur Urol. 2005;47:111–7.PubMedCrossRef Eisenhardt A, Frey U, Tack M, et al. Expression analysis and potential functional role of the CXCR4 chemokine receptor in bladder cancer. Eur Urol. 2005;47:111–7.PubMedCrossRef
14.
Zurück zum Zitat Retz MM, Sidhu SS, Blaveri E, et al. CXCR4 expression reflects tumor progression and regulates motility of bladder cancer cells. Int J Cancer. 2005;114:182–9.PubMedCrossRef Retz MM, Sidhu SS, Blaveri E, et al. CXCR4 expression reflects tumor progression and regulates motility of bladder cancer cells. Int J Cancer. 2005;114:182–9.PubMedCrossRef
15.
Zurück zum Zitat Rigo A, Gottardi M, Damiani E, et al. CXCL12 and [N33A]CXCL12 in 5637 and HeLa cells: regulating HER1 phosphorylation via calmodulin/calcineurin. PLoS One. 2012;7:e34432.PubMedCrossRef Rigo A, Gottardi M, Damiani E, et al. CXCL12 and [N33A]CXCL12 in 5637 and HeLa cells: regulating HER1 phosphorylation via calmodulin/calcineurin. PLoS One. 2012;7:e34432.PubMedCrossRef
16.
Zurück zum Zitat Greten FR, Karin M. Peering into the aftermath: JAKi rips STAT3 in cancer. Nat Med. 2010;16:1085–7.PubMedCrossRef Greten FR, Karin M. Peering into the aftermath: JAKi rips STAT3 in cancer. Nat Med. 2010;16:1085–7.PubMedCrossRef
17.
Zurück zum Zitat Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009;9:798–809.PubMedCrossRef Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009;9:798–809.PubMedCrossRef
18.
Zurück zum Zitat Chen CL, Cen L, Kohout J, et al. Signal transducer and activator of transcription 3 activation is associated with bladder cancer cell growth and survival. Mol Cancer. 2008;7:78.PubMedCrossRef Chen CL, Cen L, Kohout J, et al. Signal transducer and activator of transcription 3 activation is associated with bladder cancer cell growth and survival. Mol Cancer. 2008;7:78.PubMedCrossRef
19.
Zurück zum Zitat Chen RJ, Ho YS, Guo HR, et al. Rapid activation of Stat3 and ERK1/2 by nicotine modulates cell proliferation in human bladder cancer cells. Toxicol Sci. 2008;104:283–93.PubMedCrossRef Chen RJ, Ho YS, Guo HR, et al. Rapid activation of Stat3 and ERK1/2 by nicotine modulates cell proliferation in human bladder cancer cells. Toxicol Sci. 2008;104:283–93.PubMedCrossRef
20.
Zurück zum Zitat Ho PL, Lay EJ, Jian W, Parra D, Chan KS. Stat3 activation in urothelial stem cells leads to direct progression to invasive bladder cancer. Cancer Res. 2012;72:3135–42.PubMedCrossRef Ho PL, Lay EJ, Jian W, Parra D, Chan KS. Stat3 activation in urothelial stem cells leads to direct progression to invasive bladder cancer. Cancer Res. 2012;72:3135–42.PubMedCrossRef
21.
Zurück zum Zitat Schust J, Sperl B, Hollis A, et al. Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Chem Biol. 2006;13:1235–42.PubMedCrossRef Schust J, Sperl B, Hollis A, et al. Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Chem Biol. 2006;13:1235–42.PubMedCrossRef
22.
Zurück zum Zitat Yu CL, Meyer DJ, Campbell GS, et al. Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science. 1995;269:81–3.PubMedCrossRef Yu CL, Meyer DJ, Campbell GS, et al. Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science. 1995;269:81–3.PubMedCrossRef
23.
Zurück zum Zitat Saxman SB, Propert KJ, Einhorn LH, et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1997;15:2564–9.PubMed Saxman SB, Propert KJ, Einhorn LH, et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1997;15:2564–9.PubMed
24.
Zurück zum Zitat Molyneaux KA, Zinszner H, Kunwar PS, et al. The chemokine SDF1/CXCL12 and its receptor CXCR4 regulate mouse germ cell migration and survival. Development. 2003;130:4279–86.PubMedCrossRef Molyneaux KA, Zinszner H, Kunwar PS, et al. The chemokine SDF1/CXCL12 and its receptor CXCR4 regulate mouse germ cell migration and survival. Development. 2003;130:4279–86.PubMedCrossRef
25.
Zurück zum Zitat Zhou Y, Larsen PH, Hao C, et al. CXCR4 is a major chemokine receptor on glioma cells and mediates their survival. J Biol Chem. 2002;277:49481–7.PubMedCrossRef Zhou Y, Larsen PH, Hao C, et al. CXCR4 is a major chemokine receptor on glioma cells and mediates their survival. J Biol Chem. 2002;277:49481–7.PubMedCrossRef
26.
Zurück zum Zitat Brand S, Dambacher J, Beigel F, et al. CXCR4 and CXCL12 are inversely expressed in colorectal cancer cells and modulate cancer cell migration, invasion and MMP-9 activation. Exp Cell Res. 2005;310:117–30.PubMedCrossRef Brand S, Dambacher J, Beigel F, et al. CXCR4 and CXCL12 are inversely expressed in colorectal cancer cells and modulate cancer cell migration, invasion and MMP-9 activation. Exp Cell Res. 2005;310:117–30.PubMedCrossRef
27.
Zurück zum Zitat Brule S, Friand V, Sutton A, et al. Glycosaminoglycans and syndecan-4 are involved in SDF-1/CXCL12-mediated invasion of human epitheloid carcinoma HeLa cells. Biochim Biophys Acta. 2009;1790:1643–50.PubMedCrossRef Brule S, Friand V, Sutton A, et al. Glycosaminoglycans and syndecan-4 are involved in SDF-1/CXCL12-mediated invasion of human epitheloid carcinoma HeLa cells. Biochim Biophys Acta. 2009;1790:1643–50.PubMedCrossRef
28.
Zurück zum Zitat Friand V, Haddad O, Papy-Garcia D, et al. Glycosaminoglycan mimetics inhibit SDF-1/CXCL12-mediated migration and invasion of human hepatoma cells. Glycobiology. 2009;19:1511–24.PubMedCrossRef Friand V, Haddad O, Papy-Garcia D, et al. Glycosaminoglycan mimetics inhibit SDF-1/CXCL12-mediated migration and invasion of human hepatoma cells. Glycobiology. 2009;19:1511–24.PubMedCrossRef
29.
Zurück zum Zitat Tan CT, Chu CY, Lu YC, et al. CXCL12/CXCR4 promotes laryngeal and hypopharyngeal squamous cell carcinoma metastasis through MMP-13-dependent invasion via the ERK1/2/AP-1 pathway. Carcinogenesis. 2008;29:1519–27.PubMedCrossRef Tan CT, Chu CY, Lu YC, et al. CXCL12/CXCR4 promotes laryngeal and hypopharyngeal squamous cell carcinoma metastasis through MMP-13-dependent invasion via the ERK1/2/AP-1 pathway. Carcinogenesis. 2008;29:1519–27.PubMedCrossRef
30.
Zurück zum Zitat Ahr B, Denizot M, Robert-Hebmann V, et al. Identification of the cytoplasmic domains of CXCR4 involved in Jak2 and STAT3 phosphorylation. J Biol Chem. 2005;280:6692–700.PubMedCrossRef Ahr B, Denizot M, Robert-Hebmann V, et al. Identification of the cytoplasmic domains of CXCR4 involved in Jak2 and STAT3 phosphorylation. J Biol Chem. 2005;280:6692–700.PubMedCrossRef
31.
Zurück zum Zitat Pfeiffer M, Hartmann TN, Leick M, et al. Alternative implication of CXCR4 in JAK2/STAT3 activation in small cell lung cancer. Br J Cancer. 2009;100:1949–56.PubMedCrossRef Pfeiffer M, Hartmann TN, Leick M, et al. Alternative implication of CXCR4 in JAK2/STAT3 activation in small cell lung cancer. Br J Cancer. 2009;100:1949–56.PubMedCrossRef
32.
Zurück zum Zitat Wang M, Chen GY, Song HT, et al. Significance of CXCR4, phosphorylated STAT3 and VEGF-A expression in resected non-small cell lung cancer. Exp Ther Med. 2011;2:517–22.PubMed Wang M, Chen GY, Song HT, et al. Significance of CXCR4, phosphorylated STAT3 and VEGF-A expression in resected non-small cell lung cancer. Exp Ther Med. 2011;2:517–22.PubMed
33.
Zurück zum Zitat Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001;410:50–6.PubMedCrossRef Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001;410:50–6.PubMedCrossRef
34.
Zurück zum Zitat Scozzafava A, Mastrolorenzo A, Supuran CT. Non-peptidic chemokine receptors antagonists as emerging anti-HIV agents. J Enzyme Inhib Med Chem. 2002;17:69–76.PubMedCrossRef Scozzafava A, Mastrolorenzo A, Supuran CT. Non-peptidic chemokine receptors antagonists as emerging anti-HIV agents. J Enzyme Inhib Med Chem. 2002;17:69–76.PubMedCrossRef
35.
Zurück zum Zitat Wang Z, Ma Q, Liu Q, et al. Blockade of SDF-1/CXCR4 signalling inhibits pancreatic cancer progression in vitro via inactivation of canonical Wnt pathway. Br J Cancer. 2008;99:1695–703.PubMedCrossRef Wang Z, Ma Q, Liu Q, et al. Blockade of SDF-1/CXCR4 signalling inhibits pancreatic cancer progression in vitro via inactivation of canonical Wnt pathway. Br J Cancer. 2008;99:1695–703.PubMedCrossRef
Metadaten
Titel
CXCR4-mediated Stat3 activation is essential for CXCL12-induced cell invasion in bladder cancer
verfasst von
Hai-bo Shen
Zheng-qin Gu
Kang Jian
Juan Qi
Publikationsdatum
01.06.2013
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 3/2013
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-0725-z

Weitere Artikel der Ausgabe 3/2013

Tumor Biology 3/2013 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.